Bombay HC supports GSK in Paxil trademark fight over alleged decades of non use

A mark granted over 20 years ago may be removed

The Bombay High Court backed GSK’s Indian unit in its Paxil trademark dispute with Shreya Life Sciences. GSK argued that while Shreya secured the mark more than two decades ago, it never used it for pharmaceutical and medicinal preparations. That, GSK said, makes the registration liable for removal under Section 47 of the Trade Marks Act.